BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

BioAge Labs, Inc.NASDAQ: BIOA

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt falls 80.7% from a year ago

Short-term debt stood at $1.16M at the end of Q1 FY2026, down 80.7% from a year earlier and down 56.2% from the prior quarter. Over 3 fiscal years it compounded at +151.2% a year.

Context

  • Short-term debt amounted to 0.3% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -80.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.16M-56.2% QoQ
Last fiscal yearDec 2025
$2.65M-55.9% YoY
Year agoMar 2025
$6M-80.7% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.7%——
1 year-55.9%——
3-year CAGR+151.2%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
2.65M USD
Year-over-year change
-55.9%
3-year CAGR
+151.2%

Short-term Debt vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -80.7% is the lowest of 3, against a peer median of +101.4%.
  • Short-term debt amounts to 0.3% of total assets for BIOA, versus a peer median of 1.5%.
BIOA Competitors
Short-term Debt for BIOA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CABACabaletta Bio, Inc.Mar 2026$23.12M USD——15.6%
CGCCanopy Growth CorporationMar 2026CA$16.24M CAD+281.3%-65.6%1.5%
EDITEditas Medicine, Inc.Mar 2026$14.2M USD——9.5%
ALLOAllogene Therapeutics, Inc.Mar 2026$8.42M USD——2.1%
ACBAurora Cannabis Inc.Mar 2026CA$5.74M CAD-78.5%-66.1%1.0%
TKNOAlpha Teknova, Inc.Mar 2026$1.92M USD——1.9%
BIOABioAge Labs, Inc.Mar 2026$1.16M USD-80.7%+151.2%0.3%
LFCRLifecore Biomedical, Inc.Dec 2025$773K USD——0.3%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K USD——0.2%
HUMAHumacyte, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding BIOA) —+101.4%-65.9%1.5%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.64M21.64M354.35M188.89M
Short-term Investments00092.21M
Net Receivables000769K
Inventory0000
Other Current Assets386K3.66M2.75M4.93M
Total Current Assets28.03M25.31M357.1M286.79M
Property, Plant & Equipment (Net)374K518K791K3.75M
Goodwill0000
Intangible Assets0000
Long-term Investments0100K100K100K
Tax Assets0000
Other Non-current Assets25K0240K4.25M
Total Non-current Assets399K618K1.13M8.1M
Total Assets28.43M25.92M358.23M294.89M
Account Payables2.26M1.87M2M2.67M
Short-term Debt167K44.86M6M2.65M
Tax Payables0000
Deferred Revenue03.31M7.83M5.75M
Other Current Liabilities24K1.39M417K525K
Total Current Liabilities5.86M58.17M27.78M20.14M
Long-term Debt2.25M8.2M2.5M2.33M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)004.67M0
Other Non-current Liabilities132.88M132.95M156K370K
Total Non-current Liabilities135.13M141.15M7.33M2.7M
Total Liabilities140.99M199.32M35.11M22.84M
Common Stock0000
Retained Earnings(117.85M)(181.7M)(252.81M)(333.42M)
Accumulated OCI167K164K245K278K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(112.56M)(173.4M)323.13M272.05M
Total Debt2.47M53.25M8.7M5.56M
Net Debt(25.18M)31.61M(345.65M)(183.33M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.